ClinicalTrials.gov
public full text
Public Domain
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia#883912
- Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia#1074439
- A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia#882933
- A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.#905449
- A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules#877119
Record · ID 912991
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive